Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NOX-G15
- Development stage
- Preclinical
- Lead developer
- TME Pharma
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous (based On Typical Administration Route For Similar Aptamers; Specific Route Not Explicitly Stated)
01
Overview
NOX-G15 is a Spiegelmer® (mirror-image oligonucleotide aptamer) designed to bind and inhibit glucagon, a peptide hormone that raises blood glucose levels. By selectively neutralizing endogenous glucagon, NOX-G15 aims to reduce hyperglycemia in diabetes. It is a mixed DNA/RNA aptamer with high affinity for glucagon (Kd of 3 nM), showing no cross-reactivity with related peptides such as GLP-1, GLP-2, GIP, or prepro-vasoactive intestinal peptide. In vitro studies demonstrate that NOX-G15 inhibits glucagon-stimulated cAMP production in cells expressing the human glucagon receptor (IC50 of 3.4 nM). In animal models of type 1 and type 2 diabetes, a single injection of NOX-G15 acutely improved glucose tolerance by attenuating hyperglycemia[6][10].
02
Targets
GCG (Glucagon)GLP1R (GLP-1R)
Beyond the preview
Go deeper on NOX-G15.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NOX-G15.